
Danielle Drachmann
Danielle Drachmann is the Founder and President of Ketotic Hypoglycemia International (KHI), a global patient-led organization advancing the understanding, research, recognition, and care of Ketotic Hypoglycemia (KH).
Her leadership is rooted in both lived experience and scientific inquiry. After Danielle and her children were diagnosed with Idiopathic Ketotic Hypoglycemia (IKH), she recognized significant gaps in clinical knowledge, research, and patient support. Rather than accepting those gaps, she built KHI to bring patients, caregivers, physicians, researchers, and healthcare leaders together to help answer questions that had remained largely unexplored for decades.
With a Master’s degree in Anthropology of Health, Danielle has become a leading voice in patient-driven research and rare disease advocacy. She has helped establish a model in which lived experience is transformed into research questions, patient observations inform scientific investigation, and families become active partners in advancing medical knowledge.
Danielle is a published co-author of multiple peer-reviewed scientific publications on Ketotic Hypoglycemia. Her work includes the landmark Orphanet Journal of Rare Diseases publication, “Towards Enhanced Understanding of Idiopathic Ketotic Hypoglycemia,” which helped establish a framework distinguishing physiological from pathological Ketotic Hypoglycemia and formally introduced KHI to the scientific community. She subsequently co-authored research identifying Ketotic Hypoglycemia in individuals with Down syndrome and contributed to “Idiopathic Pathological Ketotic Hypoglycemia: Finding the Needle in a Haystack,” advancing the scientific conversation around severe, recurrent, and unexplained forms of KH.
Her work extends beyond publication. Danielle has contributed to international rare disease policy and patient engagement initiatives, represented patient perspectives within European healthcare discussions, and championed citizen science as a mechanism for accelerating discovery in underrecognized conditions.
Through KHI, Danielle continues to build international collaboration among families, pediatric endocrinologists, metabolic specialists, geneticists, researchers, healthcare institutions, and rare disease partners. Her leadership is helping move Ketotic Hypoglycemia from an often-overlooked clinical presentation toward a field of growing scientific investigation.
Danielle’s vision for KHI is clear: bring patients and science together to ask better questions, generate stronger evidence, improve clinical understanding, and ultimately create better outcomes for every person affected by Ketotic Hypoglycemia.















